Drug intelligence / Profile preview

BI 705564

Development stage: Discontinued
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

BI 705564 is an orally administered, small molecule inhibitor of Bruton's tyrosine kinase (BTK) developed by Boehringer Ingelheim. It was investigated primarily for the treatment of systemic lupus erythematosus (SLE). The drug acts by inhibiting BTK, leading to reduced B-cell activation and effects on allergic skin responses. Clinical studies demonstrated efficient target engagement, inhibition of ex vivo B-cell activation, and proof of mechanism in allergic responses. Mild bleeding-related adverse events were observed, likely due to inhibition of platelet aggregation via BTK inhibition[1][2][3][4][5].

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on BI 705564.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 705564.

Explore the full profile